HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.
To fight U.S. tariffs, Canada should suspend U.S. patents on medicines, one expert argues
Now that the Trump administration has imposed 25% tariffs on goods from Canada, the Canadian government is levying tariffs in return. But other measures are